Shopping Cart
Remove All
Your shopping cart is currently empty
Paridiprubart (NI-0101) is a humanised monoclonal antibody targeting TLR4, demonstrating ameliorative effects in COVID-19 patients with acute respiratory distress syndrome (ARDS) and holding potential for rheumatoid arthritis research.
| Pack Size | Price | USA Warehouse | Global Warehouse | Quantity |
|---|---|---|---|---|
| 1 mg | $158 | - | In Stock | |
| 5 mg | $396 | - | In Stock | |
| 10 mg | $645 | - | In Stock | |
| 25 mg | $997 | - | In Stock | |
| 50 mg | $1,330 | - | In Stock |
| Description | Paridiprubart (NI-0101) is a humanised monoclonal antibody targeting TLR4, demonstrating ameliorative effects in COVID-19 patients with acute respiratory distress syndrome (ARDS) and holding potential for rheumatoid arthritis research. |
| In vitro | In rheumatoid arthritis (RA) patients, monocytes pretreated with Paridiprubart (20 μg/mL for 30 minutes) significantly inhibited proinflammatory cytokine production induced by rheumatoid arthritis synovial fluid (RASF) [1]. Paridiprubart suppressed TNF-α secretion in macrophages stimulated by citrus limon acidified fibrinogen immune complexes (cFb-IC) through an Fc-dependent pathway [1]. |
| Synonyms | NI-0101, NI0101 |
| Reactivity | Human |
| Application | Functional assay |
| Antibody Type | Monoclonal |
| Endotoxin | <1.0 EU/mg |
| Conjucates | Unconjugated |
| Gene ID | |
| Uniprot ID | |
| Target | TLR4 |
| Molecular Weight | 145.16 kDa |
| Cas No. | 2641646-59-3 |
| Color | Transparent |
| Appearance | Liquid |
| Isotype | Human IgG1 kappa |
| Recommended Isotype Control |
| Storage | store at low temperature | store at -20°C | Shipping with blue ice/Shipping at ambient temperature. |
| Size | Quantity | Unit Price | Amount | Operation |
|---|

Copyright © 2015-2026 TargetMol Chemicals Inc. All Rights Reserved.